{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gilenya&page=2",
    "query": {
      "intervention": "Gilenya",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gilenya&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-20T02:47:33.143Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00099736",
      "title": "Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "MMF 2 g + full-dose Neoral (FDN) + corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 696,
      "start_date": "2003-05-07",
      "completion_date": "2005-09-19",
      "has_results": false,
      "last_update_posted_date": "2017-08-22",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 42,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099736"
    },
    {
      "nct_id": "NCT01201356",
      "title": "Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4125,
      "start_date": "2010-09-13",
      "completion_date": "2018-10-19",
      "has_results": true,
      "last_update_posted_date": "2021-04-21",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 34,
      "location_summary": "Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01201356"
    },
    {
      "nct_id": "NCT02141022",
      "title": "Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Cognitive Deficits",
        "Gilenya Modifying Therapy for MS"
      ],
      "interventions": [
        {
          "name": "plasticity-based computerized cognitive remediation program",
          "type": "OTHER"
        },
        {
          "name": "Gileyna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-08",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-05-10",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02141022"
    },
    {
      "nct_id": "NCT05141669",
      "title": "Impact of Fingolimod Adherence on Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 694,
      "start_date": "2020-05-18",
      "completion_date": "2020-11-20",
      "has_results": false,
      "last_update_posted_date": "2021-12-16",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05141669"
    },
    {
      "nct_id": "NCT01892722",
      "title": "Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo i.m. injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 240,
      "start_date": "2013-07-26",
      "completion_date": "2030-02-18",
      "has_results": true,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892722"
    },
    {
      "nct_id": "NCT06408259",
      "title": "Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 194,
      "start_date": "2025-04-08",
      "completion_date": "2036-07-13",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 12,
      "location_summary": "Loma Linda, California • Sacramento, California • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06408259"
    },
    {
      "nct_id": "NCT01442194",
      "title": "Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "other disease-modifying therapy",
          "type": "DRUG"
        },
        {
          "name": "Fingolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3076,
      "start_date": "2011-08-01",
      "completion_date": "2020-07-10",
      "has_results": false,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 208,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 181 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01442194"
    },
    {
      "nct_id": "NCT05528666",
      "title": "Risk Perception in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "High Efficacy Therapy (HET)",
          "type": "OTHER"
        },
        {
          "name": "Non High Efficacy Therapy (Non-HET)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 4361,
      "start_date": "2021-09-09",
      "completion_date": "2021-09-17",
      "has_results": false,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05528666"
    },
    {
      "nct_id": "NCT00731692",
      "title": "This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "FTY720",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 970,
      "start_date": "2008-07-28",
      "completion_date": "2015-06-22",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 33,
      "location_summary": "Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00731692"
    },
    {
      "nct_id": "NCT05285878",
      "title": "Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Fibrosis",
        "Kidney Transplant; Complications",
        "Kidney Transplant Rejection",
        "Kidney Transplant Failure and Rejection",
        "Kidney Transplant Failure",
        "Kidney Failure, Chronic",
        "Graft Rejection"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-07-28",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-09-20T02:47:33.143Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05285878"
    }
  ]
}